Sublingual allergy tablet launches in Canada; Elixir demonstrates new stent;

> ALK's ragweed sublingual allergy immunotherapy tablet, licensed to Merck ($MRK), just launched in Canada. Release

> Elixir Medical successfully demonstrated its DESolve 100 bioresorbable stent at the EuroPCR conference in Paris. Release

> Stanford researchers are developing small implants to be placed deep inside the body. These machines could someday replace pain medications, the scientists say. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.